Abbott Laboratories Stock Surges 035% with 74th Rank in Trading Volume

On May 6, 2025, Abbott Laboratories (ABT) saw a 0.35% increase in its stock price, with a trading volume of $833 million, ranking it 74th in the day's trading activity.

Abbott Laboratories reported significant growth in its diabetes segment and strong first-quarter sales during its earnings call. The company's nutrition division also performed well, contributing to overall positive financial results. The company's revenue for 2024 was $41.95 billion, marking a 4.59% increase from the previous year. Earnings for the year were $13.35 billion, a substantial increase of 134.19%.

Abbott Laboratories has integrated its FreeStyle Libre continuous glucose monitoring technology with Epic's electronic health record system. This collaboration aims to provide healthcare professionals with seamless access to glucose monitoring information, enhancing patient care and management.

Abbott Laboratories has initiated a new clinical trial for its AVEIR Conduction System Pacing technology. The trial follows successful implantation of the company's AVEIR Conduction System Pacing leadless pacemaker in a first-in-human study. This development underscores Abbott's commitment to advancing cardiac care through innovative technologies.

Abbott Laboratories reported strong first-quarter results, with GAAP diluted EPS of $0.76 and adjusted diluted EPS of $1.09. The company's reported sales growth was 4.0%, with organic sales growth of 6.9% or 8.3% when excluding COVID-19 testing products. These results reflect Abbott's robust performance in medical devices and nutritional products, which offset weaknesses in other segments.